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Ischemic preconditioning (IP) was originally defined as the
enhancement of myocardial tolerance against infarction
induced by a brief sublethal episode of ischemia in experi-
mental animals (1,2). Subsequently, the concept of IP was
expanded and currently includes protection against myocar-
dial stunning, arrhythmia, and vascular dysfunction after
ischemia/reperfusion injury (3–6). Results of clinical studies
conducted over the past decade support the notion that IP
occurs in human hearts, with one such situation being
pre-infarct angina, which has been shown to protect pa-
tients with myocardial infarction in terms of infarct size,
contractile dysfunction, vascular response to thrombolytic
agents, and prognosis (7–11).
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Most of the earlier clinical studies on IP focused on the
impact of IP-inducing ischemia on the outcome in patients,
and attention has not been paid to differences in responses
to IP in patients other than elderly patients (12,13). In this
issue of the Journal, Laskey and Beach (14) examined, for
the first time, the myocardial responsiveness to IP in
individual patients by using ST shift as a surrogate end point
of IP and its correlation with their prognosis. They found
that 20% of the patients undergoing elective percutaneous
coronary intervention (PCI) failed to manifest IP and that
female gender and diabetes mellitus were more prevalent in
those non-IP responders. More importantly, event-free
survival was found to be significantly poorer in the non-IP
responders than in the IP responders. Multivariate analysis
confirmed that preserved electrocardiogram (ECG) re-
sponse to IP was independently associated with a 55%
reduction of cardiac events during a one year follow-up
period.
It is not clear why PCI procedure failed to elicit IP in
20% of the patients in the study by Laskey and Beach (14).
However, it is attributable to alteration in their myocardial
and/or collateral responses to repetitive ischemia because
the protocol of PCI was the same for all of the subjects.
Although no quantitative measurement was made for cor-
onary collaterals in this study, collateral recruitment is
unlikely to be a major mechanism of IP detected at the
second 90-s coronary occlusion. Firstly, ST elevation during
the first balloon inflation was significantly larger in the IP
responders than in the non-IP responders, and this finding
argues against the possibility that the IP group included
more patients with developed coronary collaterals. Secondly,
the duration of coronary occlusion was short (90 s), and the
number of coronary occlusions was small for recruitment of
collateral flow. An earlier study by Billinger et al. (15)
showed that collateral flow significantly increased at the
third but not at the second 120-s coronary balloon inflation.
Even then, such an increase in collateral flow could account
for only 30% of the change in ST shift, indicating the
presence of a collateral flow-independent mechanism.
Thirdly, attenuation of ischemia-induced ST elevation by
IP has been demonstrated in swine hearts, which essentially
lack coronary collaterals (16). Taken together, these findings
suggest that patients who failed to show ECG phenotype of
IP had lost their myocardial ability to respond to IP stimuli.
Because ST shift is a surrogate end point of IP, the
preserved response to IP identified by this end point does
not necessarily ensure that IP mechanisms against infarc-
tion, arrhythmias, and vascular injury are indeed preserved.
However, there are overlaps in the mechanisms of IP against
each of these end points (2–6), which generally consist of
signal transduction triggered by activated G-protein-
coupled receptors (GPCRs), leading to activation of end-
effectors, including the ATP-sensitive K channel (KATP
channel). Theoretically, impairment of any of these steps
should make the heart non-responsive to IP stimuli. In fact,
we recently found that post-infarct ventricular remodeling
impairs the IP mechanism by interruption of its signal
transduction (17,18). Clinical studies using ST shift as an
end point of IP have suggested that -adrenergic, adeno-
sine, and opioid receptors as well as KATP channels contrib-
ute to IP in human hearts as in experimental animals (19).
Furthermore, a crucial role of the KATP channel in IP
protection as a mechanism downstream of the GPCRs has
been demonstrated in human cardiac tissues in vitro (20,21).
Therefore, a plausible explanation for the higher prevalence
of diabetic patients in the non-IP responders is that auto-
nomic diabetic neuropathy prevented IP ischemia from
activating GCRP receptors relevant to IP. It is also possible
that sulfonylureas administered for plasma glucose control
blocked cardiac KATP channels, preventing IP response in
some diabetic patients. Association of female gender with
lack of response to IP is an interesting finding and warrants
further investigation because a recent study has shown that
IP failed to reduce infarct size in oophorectomized female
mice (22).
The significant association between loss of myocardial
response to IP and poor prognosis is an important novel
finding in the study by Laskey and Beach (14). This
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association could be either causally related or a result of
association via a common cause. However, clinical evidence
supports the notion that angina protects human hearts from
lethal and sublethal cardiac events. In addition to protective
effects of pre-infarct angina on prognosis after infarction,
there are two other notable features of angina or a brief
ischemic episode that would prevent cardiac events. One is
the improvement of coronary endothelial function, and the
other is suppression of ischemia-induced arrhythmias. En-
dothelial dysfunction is of prime importance in develop-
ment of atherosclerosis and cardiovascular events (23–25),
and IP protects coronary endothelial function in animal
models of ischemia/reperfusion injury via opening of the
KATP channel (5,6). Furthermore, such vascular protective
effects of IP have been demonstrated in humans (26), and
the Impact of Nicorandil in Angina (IONA) trial (27)
showed that a KATP channel opener significantly reduced
the incidence of cardiac events in high-risk stable angina
patients. Anti-arrhythmic effects of IP in humans (28,29)
may be even more important because ventricular arrhyth-
mias are believed to be a major cause of pre-hospital death
in patients with acute myocardial infarction. A recent study
by Edwards et al. (28) demonstrated that IP with exercise-
induced myocardial ischemia not only suppressed ST shifts
but also markedly reduced ventricular arrhythmias, includ-
ing ventricular tachycardia and fibrillation, during subse-
quent ischemia. Taken together, circumstantial evidence
favors a causal relationship between myocardial response to
IP at the time of PCI and improved prognosis after PCI.
Regardless of the reason, the close association of ECG
phenotype of IP at the time of PCI with prognosis in
patients with coronary artery disease indicates that ST-shift
response during PCI may be useful for stratifying the risk of
future cardiac events. However, several questions need to be
answered to characterize the ST response to IP as a risk
factor. Is the criterion of IP in the present study (i.e., more
than 33% reduction of ST elevation during coronary balloon
inflation) the most appropriate for identifying patients at
high risk? Is there no difference between causes of death in
the IP responders and non-responders? Do any of the
pharmacologic agents interfere with the validity of the ST
shift for detecting IP? This issue is particularly important
for diabetic patients receiving sulfonylurea, because this
agent inhibits the sarcolemmal KATP channel that contrib-
utes to ischemia-induced ST shifts (30). Another drug that
can modify ischemia-induced ST shift is nitroglycerin,
which could mimic IP (31). Large-scale clinical studies are
necessary to address these questions in the future.
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